0001883850-22-000143.txt : 20221230 0001883850-22-000143.hdr.sgml : 20221230 20221230161022 ACCESSION NUMBER: 0001883850-22-000143 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221228 FILED AS OF DATE: 20221230 DATE AS OF CHANGE: 20221230 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: COLES N ANTHONY CENTRAL INDEX KEY: 0001197018 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 221502084 MAIL ADDRESS: STREET 1: MORRIS CORP. CENTER I; BLDG. B; 4TH FLR. STREET 2: 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2022-12-28 0 0000872589 REGENERON PHARMACEUTICALS, INC. REGN 0001197018 COLES N ANTHONY 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 1 0 0 0 Common Stock 2022-12-28 4 M 0 2145 374.12 A 3238 D Common Stock 2022-12-28 4 M 0 3613 482.68 A 6851 D Common Stock 2022-12-28 4 S 0 181 707.87 D 6670 D Common Stock 2022-12-28 4 S 0 1 709.92 D 6669 D Common Stock 2022-12-28 4 S 0 679 710.63 D 5990 D Common Stock 2022-12-28 4 S 0 100 711.95 D 5890 D Common Stock 2022-12-28 4 S 0 1198 713.66 D 4692 D Common Stock 2022-12-28 4 S 0 1022 714.61 D 3670 D Common Stock 2022-12-28 4 S 0 2266 715.48 D 1404 D Common Stock 2022-12-28 4 S 0 311 716.08 D 1093 D Non-Qualified Stock Option (right to buy) 374.12 2022-12-28 4 M 0 2145 0.0 D 2030-01-02 Common Stock 2145 0 D Non-Qualified Stock Option (right to buy) 482.68 2022-12-28 4 M 0 3613 0.0 D 2031-01-04 Common Stock 3613 0 D Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Represents volume-weighted average price of sales of 679 shares of Company stock on December 28, 2022 at prices ranging from $710.48 to $710.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price. Represents volume-weighted average price of sales of 1,198 shares of Company stock on December 28, 2022 at prices ranging from $713.17 to $713.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price. Represents volume-weighted average price of sales of 1,022 shares of Company stock on December 28, 2022 at prices ranging from $714.00 to $714.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price. Represents volume-weighted average price of sales of 2,266 shares of Company stock on December 28, 2022 at prices ranging from $715.04 to $715.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price. Represents volume-weighted average price of sales of 311 shares of Company stock on December 28, 2022 at prices ranging from $716.02 to $716.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price. On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. By: Richard Gluckselig as attorney-in-fact For: N. Anthony Coles 2022-12-29